Overall, immune checkpoint inhibition represents an innovative therapeutic approach for colorectal cancer, as antibodies inhibiting PD-1 and CD47 will restore patients’ immune competence and regain the ability to eliminate cancer cells. This evidence concerns the gene CD47 and cancer.